ELIZABETH OESTREICH is Vice President, Regulatory Compliance at Greenleaf Health Inc., where she brings a diverse background of legal, public policy, and non-profit sector knowledge to her position. In her consultation of drug and medical device clients, she works to remediate compliance issues by reviewing Form 483 and warning letter responses, offering guidance on how to build a culture of quality within a company, and providing tips for communicating global quality improvements to FDA. In addition, she advises clients navigating the regulatory landscape for tobacco products and offers guidance on content and format of applications, interpretation of FDA regulation, communication with the FDA, and analysis of proposed rules. Ms. Oestreich also works with clients in the Cannabidiol space, offering strategic guidance and risk-based strategies as the FDA contemplates how to regulate the product category. Prior to joining Greenleaf Health, she served as Director of Educational Programming for the Food and Drug Law Institute (FDLI) in Washington, DC. While at FDLI, she gained extensive experience in all FDA-regulated product areas through regularly corresponding with FDA officials, as well as creating and supervising the development of curricula for an array of educational programs. She earned a BS in Political Science from the University of Arizona and a JD from the University of the District of Columbia’s David A. Clarke School of Law.